Alkermes plc Stock
Price
Target price
€42.63
€42.63
-0.440%
-0.19
-0.440%
€46.86
06.08.26 / Stuttgart Stock Exchange
WKN: A1JKVH / Symbol: ALKS / Name: Alkermes / Stock / Biotechnology & Medical Research / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Alkermes plc Stock
The price for the Alkermes plc stock decreased slightly today. Compared to yesterday there is a change of -€0.190 (-0.440%).
With 23 Buy predictions and 1 Sell predictions Alkermes plc is one of the favorites of our community.
With a target price of 46 € there is a slightly positive potential of 7.91% for Alkermes plc compared to the current price of 42.63 €.
Pros and Cons of Alkermes plc in the next few years
Pros
?
M***** P*******
?
C******** o* t** e**********
?
B****
Cons
?
W********* I********* f** t** n*** y****
?
S********** s********
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Alkermes plc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Alkermes plc | -0.440% | -1.113% | -11.684% | 88.628% | 80.636% | 71.895% | 76.157% |
| Icon plc | 0.570% | 0.317% | -3.689% | 5.018% | -8.164% | -37.752% | - |
| United Therapeutics | -0.580% | 3.809% | -5.572% | 81.464% | 9.057% | 115.541% | 156.044% |
| Ligand Pharmaceuticals | -3.820% | -0.781% | -9.286% | 117.094% | 53.012% | 319.835% | 171.194% |
Comments
Alkermes (ALKS) had its "overweight" rating reaffirmed by Piper Sandler.
Show more
Ratings data for ALKS provided by MarketBeat
Alkermes (ALKS) had its price target raised by Needham & Company LLC from $61.00 to $62.00. They now have a "buy" rating on the stock.
Show more
Ratings data for ALKS provided by MarketBeat
Alkermes (ALKS) had its "overweight" rating reaffirmed by Wells Fargo & Company.
Show more
Ratings data for ALKS provided by MarketBeat
News
Alkermes Q2 Earnings Call Highlights
Key Points
- Interested in Alkermes plc? Here are five stocks we like better.
- Alkermes reported strong Q2 performance: Revenue reached $496 million, while proprietary product sales rose 34% year
Alkermes Touts Orexin Ambitions as Alixorexton Enters Phase 3 and CEO Transition Nears
Key Points
- Interested in Alkermes plc? Here are five stocks we like better.
- Alkermes’ lead orexin agonist, alixorexton, has entered Phase 3 with the Brilliance program now enrolling in